Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -85.80% is 52% below its 3-year average of -56.27%, near the low end of its 3-year range (-85.80%–-26.56%).
126.65% below its 12-month average of -37.85%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -17.66%.
RETURN ON ASSETS (ROA)
-85.80%
RETURN ON ASSETS (ROA) AVG TTM
-37.85%
RETURN ON ASSETS (ROA) AVG 3Y
-56.27%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-126.65%
CURRENT VS 3Y AVG
-52.49%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-24.95%
median of 438 covered companies
CURRENT VS SECTOR MEDIAN
-243.89%
vs the sector median at left
Aardvark Therapeutics, Inc. Common Stock
Market Cap
$114.24M
Return on Assets (ROA)
-85.80%
TTM Avg
-37.85%
3Y Avg
-56.27%
5Y Avg
N/A
Market Cap
$113.77M
Return on Assets (ROA)
-0.05%
TTM Avg
-38.03%
3Y Avg
-60.31%
5Y Avg
-59.32%
Market Cap
$116.59M
Return on Assets (ROA)
-128.96%
TTM Avg
-127.49%
3Y Avg
-112.64%
5Y Avg
-129.28%
Market Cap
$111.17M
Return on Assets (ROA)
-34.04%
TTM Avg
-20.59%
3Y Avg
-37.88%
5Y Avg
-37.10%
Market Cap
$117.43M
Return on Assets (ROA)
-31.75%
TTM Avg
-34.00%
3Y Avg
-32.33%
5Y Avg
-29.29%
Market Cap
$118.02M
Return on Assets (ROA)
-72.42%
TTM Avg
-66.03%
3Y Avg
-45.57%
5Y Avg
-48.77%
Market Cap
$118.50M
Return on Assets (ROA)
-167.64%
TTM Avg
-183.95%
3Y Avg
-119.46%
5Y Avg
-95.34%
Market Cap
$109.93M
Return on Assets (ROA)
-70.09%
TTM Avg
-324.97%
3Y Avg
-229.15%
5Y Avg
-168.27%
Market Cap
$118.63M
Return on Assets (ROA)
-4.60%
TTM Avg
-3.66%
3Y Avg
-5.21%
5Y Avg
-1.02%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $114.24M | -85.80% | -37.85% | -56.27% | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $113.77M | -0.05% | -38.03% | -60.31% | -59.32% |
| Genelux Corporation (GNLX)vs › | $116.59M | -128.96% | -127.49% | -112.64% | -129.28% |
| Black Diamond Therapeutics, Inc. (BDTX)vs › | $111.17M | -34.04% | -20.59% | -37.88% | -37.10% |
| Foghorn Therapeutics Inc. (FHTX)vs › | $117.43M | -31.75% | -34.00% | -32.33% | -29.29% |
| Caribou Biosciences, Inc. (CRBU)vs › | $118.02M | -72.42% | -66.03% | -45.57% | -48.77% |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $118.50M | -167.64% | -183.95% | -119.46% | -95.34% |
| Immunic, Inc. (IMUX)vs › | $109.93M | -70.09% | -324.97% | -229.15% | -168.27% |
| BGM Group Ltd. (BGM)vs › | $118.63M | -4.60% | -3.66% | -5.21% | -1.02% |
| Apyx Medical Corporation (APYX)vs › | $109.49M | -14.14% | -26.48% | -30.34% | -26.58% |
ROA
-85.8%
ROE
-93.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -49.15% |
| 2024-12-31 | -26.56% |
| 2023-12-31 | -68.41% |
| 2022-12-31 | -80.95% |
